Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.40 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16797324 | 0.86 | MAPK1 (0.46) | KDM1AMAPK1 | |
| SCHEMBL16797268 | 0.82 | KDM1A (0.52) | KDM1AMAPK1JAK2JAK1JAK3 | |
| SCHEMBL16797362 | 0.82 | KDM1A (0.63) | KDM1AMAPK1VNN1JAK2JAK1 | |
| SCHEMBL17559071 | 0.81 | KDM1A (0.66) | KDM1AMAPK1VNN1JAK2JAK1 | |
| SCHEMBL16797291 | 0.80 | KDM1A (0.58) | KDM1AVNN1JAK2JAK3EGLN2 | |
| SCHEMBL24659688 | 0.79 | KDM1A (0.56) | KDM1AMAPK1JAK2JAK3MERTK | |
| SCHEMBL16808849 | 0.79 | KDM1A (0.56) | KDM1AMAPK1JAK2JAK3MERTK | |
| SCHEMBL16797341 | 0.76 | KDM1A (0.45) | KDM1AMAPK1JAK2JAK1JAK3 | |
| SCHEMBL17559060 | 0.76 | KDM1A (0.62) | KDM1AMAPK1MERTKEGLN2ACHE | |
| SCHEMBL16797266 | 0.76 | KDM1A (0.55) | KDM1AMAPK1MERTKEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4257591-A2 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3080100-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20200108052-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-02-21 | — | — | US | disclosed |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-06-28 | — | — | US | disclosed |
| US-9944636-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9822119-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. | 2016-10-20 | — | — | US | disclosed |
| EP-3080100-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-21 | — | — | US | disclosed |
| WO-2015089192-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179204-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-20200108052-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-10131664-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-20160108046-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-20190055242-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-20160304516-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
| US-10385051-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | KDM1A 2/4885MAPK1 2360/4885VNN1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.